Real-world clinical outcomes according to individualised selexipag dose in pulmonary arterial hypertension (PAH)
Bibliographic record
Abstract
Selexipag efficacy was consistent across different dose groups in GRIPHON ( NCT01106014 ). We used real-world data from Europe/Canada to describe clinical characteristics and outcomes of PAH patients based on their maximally tolerated selexipag dose reached through titration. PAH patients treated with selexipag in the EXPOSURE/EXTRACT (EUPAS19085/EUPAS49227) observational studies were categorized into lower (≤800µg twice daily [b.i.d]) or higher (>800µg b.i.d) dose groups, using the observed median individualised dose of selexipag as cut-off. An outcome model for clinical worsening was developed using a Poisson regression adjusted for selected covariates at selexipag initiation. As of July 2023, for patients in the lower (n=492) and higher (n=341) dose groups, median age was 60 vs 58 yrs, median (Q1, Q3) time since diagnosis was 2.4 (0.8, 6.4) vs 1.8 (0.7, 5.9) yrs, and proportion with idiopathic or connective tissue disease-associated PAH was 50% and 29% vs 54% and 21%, respectively. In each group, >80% initiated selexipag as triple combination therapy. Selexipag was discontinued by 218 (44%) patients in the lower and 113 (33%) in the higher dose group, with 70 (14%) and 39 (11%) patients dying, respectively. Time to clinical worsening was similar for both groups (Figure). To conclude, similar time to clinical worsening was observed for PAH patients, regardless of individualised selexipag dose reached. erj;66/suppl_69/PA5156/F1 F1 F1
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.008 | 0.011 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".